Identifying a Case of an Atenolol-induced Papulosquamous Eruption
Main Article Content
Keywords
papulosquamous, drug eruption, atenolol, eczematous, psoriasiform, beta blocker
Abstract
While beta-adrenergic blocking agents (beta blockers) are generally safe, their incidence of medication-induced cutaneous eruptions remain under-recognized in the primary care setting. The adverse dermatologic effects of these medications may arise in the days to years following drug initiation, contributing to its delayed diagnosis and management. Here we report a case of a papulosquamous drug eruption in an older adult due to atenolol. We also discuss pertinent morphologic findings, diagnostic methods, management, and how to distinguish this type of eruption from other papulosquamous disorders.
References
2. Thomopoulos C, Bazoukis G, Tsioufis C, Mancia G. Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials. J Hypertens. 2020 Sep;38(9):1669-1681.3.
3. Tatu AL, Elisei AM, Chioncel V, Miulescu M, Nwabudike LC. Immunologic adverse reactions of β-blockers and the skin. Exp Ther Med. 2019;18(2):955-959.
4. Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM. Drugs in exacerbation of psoriasis. J Am Acad Dermatol. 1986;15(5 Pt 1):1007-1022.
5. Wu S, Han J, Li WQ, Qureshi AA. Hypertension, antihypertensive medication use, and risk of psoriasis. JAMA Dermatol. 2014;150(9):957-963.
6. Blum AE, Burgin S. Eczematous Drug Eruptions. Am J Clin Dermatol. 2021;22(3):349-366.
7. Wakefield PE, Berger TG, James WD. Atenolol-induced pustular psoriasis. Arch Dermatol. 1990;126(7):968-969.
8. Ranugha PSS, Betkerur JB. Antihypertensives in dermatology Part II - Cutaneous adverse reactions to antihypertensives. Indian J Dermatol Venereol Leprol. 2018;84(2):137-147.
9. Müller G, Lübow C, Weindl G. Lysosomotropic beta blockers induce oxidative stress and IL23A production in Langerhans cells. Autophagy. 2020;16(8):1380-1395.
10. Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol. 2003;2(3):278-299.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.